Skip to main content
Explore URMC
menu

Peter Van Veldhuizen, M.D.

Contact Information

Phone Numbers

Appointment: (585) 276-3000

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

Dr. Van Veldhuizen completed his residency training followed by a Hematology/ Oncology fellowship at the University of Kansas Medical Center. He is board-certified in Internal Medicine, Hematology, and Oncology. After spending much of his career in Kansas City where his primary clinical focus was the treatment of Genitourinary Malignancies (GU), in 2020 he joined the University of Rochester and the Wilmot Cancer Center to lead their GU Medical Oncology Program.

Dr. Van Veldhuizen sees patients with kidney, bladder, testicular, and prostate cancer. He is involved in helping formulate multidisciplinary treatment plans, administering chemotherapy, and managing symptoms related to both the cancer and its treatment. He also has a clinical focus on cancer survivorship and addressing all aspects related to the cancer diagnosis.

Professional Background

Dr. Van Veldhuizen is a Professor of Internal Medicine at the University of Rochester Medical Center and currently leads the GU Medical Oncology Program. He also serves as the chair of the Genitourinary Working Group which provides oversight and direction for the GU Clinical Trial Research Program. He also currently serves on the American Society of Clinical Oncology's (ASCO) Clinical Guidelines Committee which provides treatment guidelines for practicing Oncologists. He has served as a grant reviewer for the Department of Defense Prostate Cancer Research Program and is currently a committee member for an ASCO expert panel focusing on developing treatment guidelines for advanced kidney cancer.
Before coming to Rochester, he served as chair of the Kansas City Veteran Affairs Hematology/Oncology Program and then served as the Division Director of Hematology/ Oncology at the University of Kansas Medical Center. He is an advocate for addressing all aspects of the cancer diagnosis.

Research

Dr. Van Veldhuizen's research has focused on the development of novel clinical trials for the treatment of genitourinary malignancies. He has been a member of the National Clinical Trial Group, SWOG, and their Genitourinary Cancer (GU) Committee since 1992. He currently serves on their GU Executive Committee and is the Chairman of SWOG's GU Cancer Survivorship Subcommittee. He also serves as the GU liaison to the Cancer Control Committees helping mentor investigators in the development of Cancer Control and Survivorship projects. He has been the national Principal Investigator (PI) or primary coordinator on SWOG trials and well as the PI on local investigator-initiated studies. He has had a focused interest in collaborating with laboratory-based scientists, helping translate those findings into the clinic. His current laboratory-based research interest is evaluating the mechanism of the spread of prostate cancer to the bone.

Credentials

Specialties

  • Hematology - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

1986
MD | University of South Dakota School of Medicine

Post-doctoral Training & Residency

06/30/1989 - 06/30/1992
Fellowship in Medical Oncology at University of Kansas Medical Center

06/30/1987 - 06/30/1989
Residency in Internal Medicine at University of Kansas Medical Center

06/30/1986 - 06/30/1987
Internship in Internal Medicine at University of Kansas Medical Center

VIEW ALL expand_more

Clinical Trials

Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study

Lead Researcher: Peter Van Veldhuizen

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

View Study Details

A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer

Lead Researcher: Peter Van Veldhuizen

This is a Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant (AB928)-based combination therapy in participants with metastatic castrate resistant prostate cancer (mCRPC).

View Study Details

Publications

Journal Articles

11/5/2022
Yang J, Aljitawi O, Van Veldhuizen P. "Prostate Cancer Stem Cells: The Role of CD133." Cancers.. 2022 Nov 5; 14(21)Epub 2022 Nov 05.

10/2022
Ellis SD, Vaidya R, Unger JM, Stratton K, Gills J, Van Veldhuizen P, Mederos E, Dressler EV, Hudson MF, Kamen C, Neuman HB, Kazak AE, Carlos RC, Weaver KE. "Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey." Contemporary clinical trials communications.. 2022 Oct; 29:100981. Epub 2022 Aug 14.

6/21/2022
Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. "Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline." Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 Jun 21; :JCO2200868. Epub 2022 Jun 21.

VIEW ALL PUBLICATIONS